Developer docs
API playgroundTry for free, no card

Search company profiles

BioSquare

Full company profile

uuid00045yl

Namestring
BioSquare
Legal namestring
주식회사 바이오스퀘어
Websiteurl
bio-square.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

BioSquare is a South Korean biotechnology company founded in 2017 that develops and commercializes quantum dot-based in vitro diagnostic (IVD) devices. The company's core technology, QuantumPACK™, consists of silica-packaged semiconductor nanoparticles (Core@Shell nanostructures) that produce highly sensitive, stable, hydrophilic fluorescent signals capable of multiplex detection under a single excitation wavelength. This platform is sold as an integrated solution comprising proprietary fluorescence immunoassay analyzers (QDITS Mini, Smart, Basic, Pro, and ALFS) and a menu of consumable diagnostic assays for infectious disease (influenza, COVID-19, RSV, strep A, mycoplasma), sepsis/inflammatory markers (PCT, CRP), thyroid function (TSH, Free T4, T3), and high-value multiplex panels for Alzheimer's disease and cardiac biomarkers. A secondary NanoPACK platform provides lower-cost lateral flow antigen tests including an over-the-counter COVID-19 home test and an HIV 1/2 Ab rapid test.

BioSquare generates revenue through a razor-and-razorblade model: one-time hardware sales of QDITS analyzers and recurring sales of disposable QuantumPACK and NanoPACK test cartridges (e.g., 25 tests/kit configurations). Pricing is not publicly disclosed, but the GTM motion is enterprise field sales directed at hospitals, emergency rooms, airports, public health centers, and small-to-medium hospitals. Distribution channels include direct B2B sales in Korea, the CapitalBio Group joint venture in China (leveraging 400+ distribution points), and ODA/government channels via KOICA and CDT Africa for developing countries in East Africa. The company holds exclusive patent licenses from Seoul National University for foundational QuantumPACK patents and has registered 16+ improvement patents across Korea, the US, Japan, China, and 9 European countries. Regulatory clearances include Korea MFDS Class 3 manufacturing approvals (2022-2023), ISO 13485:2016, CE IVDR/IVDD, and an FDA registration for QuantumPACK Easy Strep A in October 2025. BioSquare has raised approximately 9.5 billion KRW (USD ~7M) across seed, pre-Series A, and Series A rounds from Korean institutional investors including LSK Investment, BNH Investment, SBI Investment, IBK Capital, and Kiwoom Investment; Series B funding is under consideration.

Short descriptiontext

BioSquare is a Korean biotechnology company founded in 2017 that develops quantum dot-based in vitro diagnostic devices and consumable assays for point-of-care infectious disease, cardiac, neurological, and inflammatory testing in hospitals, airports, and developing-country healthcare settings.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeongnam, South Korea
HQ citystring
Seongnam
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword1 value
No source data available
Product category
No source data available
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1QuantumPACK™ Diagnostic Reagents
TypeOne Time License
Description

Sale of in vitro diagnostic rapid test devices including Influenza A+B, COVID-19 Ag, RSV, Strep A and other infectious disease tests for use with QDITS™ analyzers.

bio-square.com
2QDITS™ Analyzers
TypeHardware Sales
Description

Sale of diagnostic instruments (QDITS™ Mini, Smart, Basic, Pro, ALFS) that read and analyze QuantumPACK™ and NanoPACK™ test cartridges.

bio-square.com
3QuantumPACK™ Materials and Equipment
TypeOne Time License
Description

Supply of QuantumPACK fluorescent materials and dedicated analysis equipment QDITS to enterprise customers for technology export purposes.

bio-square.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Pricing details1 tier
1QuantumPACK Easy product line
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Products sold in kit configurations (25 Tests/Kit for respiratory panels). Analyzer equipment sold separately as QDITS devices.

bio-square.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 5 records shown
1QuantumPACK™
Description

Core quantum dot-based IVD platform technology for fluorescence immunoassay diagnostics, enabling high sensitivity, high precision, and multiplex detection.

bio-square.com
+4 more records
Core offering1 text field

No source content was provided for this extraction; core offerings cannot be determined from the supplied data.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 99.12% overall accuracy in clinical trials (vs real-time PCR) for Influenza A+B detection
+1 more record
Product overview1 text field

BioSquare provides an integrated in vitro diagnostic (IVD) solution platform based on QuantumPACK technology, a quantum dot-based fluorescence immunoassay system. The portfolio consists of three main platform lines: (1) QuantumPACK Easy - lateral flow assay-based rapid tests including respiratory panels (Influenza A+B, COVID-19, RSV, Strep A), infection markers (PCT, CRP, Mycoplasma), and thyroid markers (TSH, Free T4, T3); (2) QuantumPACK Pro - high-sensitivity multiplex assays for Alzheimer's (Beta-Amyloid 40/42, Phospho-Tau 181/217, ApoE4/GFAP) and cardiac panels (Troponin/CK-MB/Myo); (3) NanoPACK - lateral flow rapid antigen tests including COVID-19 (professional and home use), HIV, Influenza A+B, and home pregnancy/ovulation tests. These assay products are run on the QDITS analyzer family (ALFS, Basic, Smart, Mini) which use fluorescence immunoassay technology for signal detection and analysis. The platform enables high-sensitivity, high-precision, and multiplex diagnostics from central laboratories to point-of-care settings.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
1Institut Pasteur Korea
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Collaborative R&D partnership for Leishmaniasis diagnostics. Institut Pasteur Korea provides rK39/K26 chimeric antigen for enhanced sensitivity. BioSquare was housed at Institut Pasteur Korea Pangyo campus as part of Bio Core Facility program.

bio-square.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Partnership with World Bank-affiliated organization for Leishmaniasis diagnostics development in East Africa. CDT Africa provides clinical specimens from Leishmaniasis patients in East Africa for product development and validation.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Collaboration for neglected tropical disease diagnostics. DNDi provides advisory support on product development aligned with current Leishmaniasis standard diagnostic and treatment methods to maximize field applicability.

4OptiBio
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Partner in Leishmaniasis diagnostic development project, participating in product development and certification processes.

bio-square.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Selected for RIGHT Fund major project for Leishmaniasis point-of-care diagnostic platform development. RIGHT Fund is co-founded by Korean Ministry of Health and Welfare, Bill & Melinda Gates Foundation, and 8 Korean life science companies (SK Bioscience, LG Chem, GC Pharma, Chong Kun Dang, Genexine, GeneOne, Y-Biologics, SD Biosensor).

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Joint venture agreement signed with CapitalBio Group, a subsidiary of Tsinghua Holdings (China's Tsinghua University technology holding company). CapitalBio has over 400 sales networks across China. The JV aims to establish local production and sales presence in China.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Selected for KOICA Creative Technology Solution (CTS) program for developing country problem-solving initiatives in low and lower-middle income countries.

8Konkuk University
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Academic-industry collaboration through LINC+ program for multi-quantum dot diagnostic kit commercialization research. Professor Jeon Bong-hyun led research on high-efficiency quantum dot nanostructure development.

bio-square.com
9Seoul National University
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2017-01-01
Description

BioSquare acquired exclusive patent licenses for QuantumPACK technology (KR1651798, KR1609618) from Seoul National University Professor Lee Yoon-sik, who developed the core quantum dot packaging technology. This forms the foundation of BioSquare's proprietary diagnostic platform.

bio-square.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Molecular diagnostics and sample-prep company expanding into decentralized testing (QIAstat-Dx). Less direct overlap than Abbott/BD but competes in the broader move from central lab to POCT molecular and immunoassay testing.

TypeEmerging player
Description

Panther molecular system and rapid antigen products overlap with BioSquare's infectious disease and women's health diagnostics portfolio. Comparable mid-cap specialty diagnostics profile with focus on decentralization of testing.

TypeEmerging player
Description

Mid-size diagnostics company with rapid test systems and chemistry/immunoassay products. Overlaps in POC infectious disease testing and serves similar hospital/clinic customer base as BioSquare.

TypeBroad incumbent
Description

FilmArray multiplex PCR system competes in syndromic infectious disease testing and broader decentralized molecular diagnostics. Representative incumbent in the move to multiplex POC testing that QuantumPACK Pro is also targeting.

TypeBroad incumbent
Description

BD Veritor System is a direct competitor in hospital and POC rapid immunoassay testing (Flu, RSV, Strep A, COVID-19). BD's scale, distribution, and hospital relationships make it a primary competitive threat in BioSquare's core segments.

TypeBroad incumbent
Description

GeneXpert molecular POCT system competes in the broader decentralized infectious disease testing market BioSquare targets. While Cepheid is molecular PCR-based (different modality), it competes for the same clinical decision points.

TypeDirect peer
Description

Korean-headquartered IVD company specializing in rapid diagnostic test kits and analyzers, with a directly overlapping respiratory infectious disease product line (Flu, COVID-19, RSV) and similar lateral flow + fluorescence immunoassay platform approach. SD Biosensor is the most direct Korean peer and serves the same hospital/clinical POC market.

TypeEmerging player
Description

Emerging diagnostics company exploring nanosensor and novel biomarker detection technologies. Less established but competes at the technology-platform level in novel immunoassay approaches.

TypeDirect peer
Description

US-based POCT specialist (Sofia platform for Flu, COVID-19, RSV, Strep A) with similar rapid immunoassay analyzer + cartridge business model targeting hospitals, urgent care, and physician offices. Closest US analog to BioSquare's QDITS + QuantumPACK Easy product system.

10Abbott Diagnostics
TypeBroad incumbent
Description

Global diagnostics leader with Binax (lateral flow) and ID NOW (molecular POCT) product lines directly competing in the same respiratory, Strep A, and infectious disease rapid testing categories as BioSquare, with vastly greater sales reach and clinical evidence budget.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance34 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioSquare

No source data availablebio-square.com

BioSquare is a Korean biotechnology company founded in 2017 that develops quantum dot-based in vitro diagnostic devices and consumable assays for point-of-care infectious disease, cardiac, neurological, and inflammatory testing in hospitals, airports, and developing-country healthcare settings.

What BioSquare does

BioSquare is a South Korean biotechnology company founded in 2017 that develops and commercializes quantum dot-based in vitro diagnostic (IVD) devices. The company's core technology, QuantumPACK™, consists of silica-packaged semiconductor nanoparticles (Core@Shell nanostructures) that produce highly sensitive, stable, hydrophilic fluorescent signals capable of multiplex detection under a single excitation wavelength. This platform is sold as an integrated solution comprising proprietary fluorescence immunoassay analyzers (QDITS Mini, Smart, Basic, Pro, and ALFS) and a menu of consumable diagnostic assays for infectious disease (influenza, COVID-19, RSV, strep A, mycoplasma), sepsis/inflammatory markers (PCT, CRP), thyroid function (TSH, Free T4, T3), and high-value multiplex panels for Alzheimer's disease and cardiac biomarkers. A secondary NanoPACK platform provides lower-cost lateral flow antigen tests including an over-the-counter COVID-19 home test and an HIV 1/2 Ab rapid test.

BioSquare generates revenue through a razor-and-razorblade model: one-time hardware sales of QDITS analyzers and recurring sales of disposable QuantumPACK and NanoPACK test cartridges (e.g., 25 tests/kit configurations). Pricing is not publicly disclosed, but the GTM motion is enterprise field sales directed at hospitals, emergency rooms, airports, public health centers, and small-to-medium hospitals. Distribution channels include direct B2B sales in Korea, the CapitalBio Group joint venture in China (leveraging 400+ distribution points), and ODA/government channels via KOICA and CDT Africa for developing countries in East Africa. The company holds exclusive patent licenses from Seoul National University for foundational QuantumPACK patents and has registered 16+ improvement patents across Korea, the US, Japan, China, and 9 European countries. Regulatory clearances include Korea MFDS Class 3 manufacturing approvals (2022-2023), ISO 13485:2016, CE IVDR/IVDD, and an FDA registration for QuantumPACK Easy Strep A in October 2025. BioSquare has raised approximately 9.5 billion KRW (USD ~7M) across seed, pre-Series A, and Series A rounds from Korean institutional investors including LSK Investment, BNH Investment, SBI Investment, IBK Capital, and Kiwoom Investment; Series B funding is under consideration.

BioSquare firmographics

Firmographics
Name
BioSquare
Legal name
주식회사 바이오스퀘어
Website
https://bio-square.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
BioSquare is a Korean biotechnology company founded in 2017 that develops quantum dot-based in vitro diagnostic devices and consumable assays for point-of-care infectious disease, cardiac, neurological, and inflammatory testing in hospitals, airports, and developing-country healthcare settings.
Ownership category
akta.pro rank

Where BioSquare is headquartered

Location

Headquarters

HQ city
Seongnam
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

BioSquare business model

Business model
GTM type
B2B
Offering type
Services

Revenue model

  1. QuantumPACK™ Diagnostic Reagents: Sale of in vitro diagnostic rapid test devices including Influenza A+B, COVID-19 Ag, RSV, Strep A and other infectious disease tests for use with QDITS™ analyzers.
  2. QDITS™ Analyzers: Sale of diagnostic instruments (QDITS™ Mini, Smart, Basic, Pro, ALFS) that read and analyze QuantumPACK™ and NanoPACK™ test cartridges.
  3. QuantumPACK™ Materials and Equipment: Supply of QuantumPACK fluorescent materials and dedicated analysis equipment QDITS to enterprise customers for technology export purposes.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goQuantumPACK Easy product line

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

BioSquare product offering

Product offering

Core offering

No source content was provided for this extraction; core offerings cannot be determined from the supplied data.

Product overview

BioSquare provides an integrated in vitro diagnostic (IVD) solution platform based on QuantumPACK technology, a quantum dot-based fluorescence immunoassay system. The portfolio consists of three main platform lines: (1) QuantumPACK Easy - lateral flow assay-based rapid tests including respiratory panels (Influenza A+B, COVID-19, RSV, Strep A), infection markers (PCT, CRP, Mycoplasma), and thyroid markers (TSH, Free T4, T3); (2) QuantumPACK Pro - high-sensitivity multiplex assays for Alzheimer's (Beta-Amyloid 40/42, Phospho-Tau 181/217, ApoE4/GFAP) and cardiac panels (Troponin/CK-MB/Myo); (3) NanoPACK - lateral flow rapid antigen tests including COVID-19 (professional and home use), HIV, Influenza A+B, and home pregnancy/ovulation tests. These assay products are run on the QDITS analyzer family (ALFS, Basic, Smart, Mini) which use fluorescence immunoassay technology for signal detection and analysis. The platform enables high-sensitivity, high-precision, and multiplex diagnostics from central laboratories to point-of-care settings.

Differentiator

Problem solved

Functional benefit

Brands

  • QuantumPACK™: Core quantum dot-based IVD platform technology for fluorescence immunoassay diagnostics, enabling high sensitivity, high precision, and multiplex detection.
  • NanoPACK™
  • QDITS™
  • QuantumPACK™ Easy
  • QuantumPACK™ Pro

Quantifiable outcome

  • 99.12% overall accuracy in clinical trials (vs real-time PCR) for Influenza A+B detection
  • +1 more outcomes

Companies that use BioSquare

Customer profile

Segments3 records

BioSquare technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

BioSquare partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core, minor and major.

  • Institut Pasteur KoreacoreStrategic or Co-development Partner · 1 January 2020Collaborative R&D partnership for Leishmaniasis diagnostics. Institut Pasteur Korea provides rK39/K26 chimeric antigen for enhanced sensitivity. BioSquare was housed at Institut Pasteur Korea Pangyo campus as part of Bio Core Facility program.
  • CDT Africa (Center for Innovative Drug Development and Therapeutic Trials for Africa)coreStrategic or Co-development Partner · 1 January 2020Partnership with World Bank-affiliated organization for Leishmaniasis diagnostics development in East Africa. CDT Africa provides clinical specimens from Leishmaniasis patients in East Africa for product development and validation.
  • DNDi (Drugs for Neglected Diseases initiative)coreStrategic or Co-development Partner · 1 January 2020Collaboration for neglected tropical disease diagnostics. DNDi provides advisory support on product development aligned with current Leishmaniasis standard diagnostic and treatment methods to maximize field applicability.
  • OptiBiominorStrategic or Co-development Partner · 1 January 2020Partner in Leishmaniasis diagnostic development project, participating in product development and certification processes.
  • RIGHT FundcoreStrategic or Co-development Partner · 1 January 2020Selected for RIGHT Fund major project for Leishmaniasis point-of-care diagnostic platform development. RIGHT Fund is co-founded by Korean Ministry of Health and Welfare, Bill & Melinda Gates Foundation, and 8 Korean life science companies (SK Bioscience, LG Chem, GC Pharma, Chong Kun Dang, Genexine, GeneOne, Y-Biologics, SD Biosensor).
  • CapitalBio Group (Tsinghua Holdings subsidiary)majorStrategic or Co-development Partner · 1 January 2018Joint venture agreement signed with CapitalBio Group, a subsidiary of Tsinghua Holdings (China's Tsinghua University technology holding company). CapitalBio has over 400 sales networks across China. The JV aims to establish local production and sales presence in China.
  • KOICAminorStrategic or Co-development Partner · 1 January 2018Selected for KOICA Creative Technology Solution (CTS) program for developing country problem-solving initiatives in low and lower-middle income countries.
  • Konkuk UniversityminorStrategic or Co-development Partner · 1 January 2018Academic-industry collaboration through LINC+ program for multi-quantum dot diagnostic kit commercialization research. Professor Jeon Bong-hyun led research on high-efficiency quantum dot nanostructure development.
  • Seoul National UniversitycoreTechnology or Integration · 1 January 2017BioSquare acquired exclusive patent licenses for QuantumPACK technology (KR1651798, KR1609618) from Seoul National University Professor Lee Yoon-sik, who developed the core quantum dot packaging technology. This forms the foundation of BioSquare's proprietary diagnostic platform.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

BioSquare competitors and assessment

Company assessment

Emerging players

  • QIAGEN: Molecular diagnostics and sample-prep company expanding into decentralized testing (QIAstat-Dx). Less direct overlap than Abbott/BD but competes in the broader move from central lab to POCT molecular and immunoassay testing.
  • Hologic: Panther molecular system and rapid antigen products overlap with BioSquare's infectious disease and women's health diagnostics portfolio. Comparable mid-cap specialty diagnostics profile with focus on decentralization of testing.
  • Sekisui Diagnostics: Mid-size diagnostics company with rapid test systems and chemistry/immunoassay products. Overlaps in POC infectious disease testing and serves similar hospital/clinic customer base as BioSquare.
  • NanoDx: Emerging diagnostics company exploring nanosensor and novel biomarker detection technologies. Less established but competes at the technology-platform level in novel immunoassay approaches.

Broad incumbents

  • BioFire Diagnostics (bioMérieux): FilmArray multiplex PCR system competes in syndromic infectious disease testing and broader decentralized molecular diagnostics. Representative incumbent in the move to multiplex POC testing that QuantumPACK Pro is also targeting.
  • Becton Dickinson (BD): BD Veritor System is a direct competitor in hospital and POC rapid immunoassay testing (Flu, RSV, Strep A, COVID-19). BD's scale, distribution, and hospital relationships make it a primary competitive threat in BioSquare's core segments.
  • Cepheid (Danaher): GeneXpert molecular POCT system competes in the broader decentralized infectious disease testing market BioSquare targets. While Cepheid is molecular PCR-based (different modality), it competes for the same clinical decision points.
  • Abbott Diagnostics: Global diagnostics leader with Binax (lateral flow) and ID NOW (molecular POCT) product lines directly competing in the same respiratory, Strep A, and infectious disease rapid testing categories as BioSquare, with vastly greater sales reach and clinical evidence budget.

Direct peers

  • SD Biosensor: Korean-headquartered IVD company specializing in rapid diagnostic test kits and analyzers, with a directly overlapping respiratory infectious disease product line (Flu, COVID-19, RSV) and similar lateral flow + fluorescence immunoassay platform approach. SD Biosensor is the most direct Korean peer and serves the same hospital/clinical POC market.
  • QuidelOrtho: US-based POCT specialist (Sofia platform for Flu, COVID-19, RSV, Strep A) with similar rapid immunoassay analyzer + cartridge business model targeting hospitals, urgent care, and physician offices. Closest US analog to BioSquare's QDITS + QuantumPACK Easy product system.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

BioSquare compliance and trust

Trust signal

Compliance34 records

BioSquare financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioSquare leadership team

Management profile

Number of profiles

BioSquare subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

BioSquare funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioSquare M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioSquare

What does BioSquare do?

No source content was provided for this extraction; core offerings cannot be determined from the supplied data.

Is BioSquare a public or private company?

BioSquare is a private company. It is classified as unknown and is currently operating.

When was BioSquare founded?

BioSquare was founded in 2017. It employs 11 to 50 people.

Where is BioSquare based?

BioSquare is headquartered in Seongnam, South Korea, in the Asia region.

How does BioSquare make money?

Three revenue lines are on record. QuantumPACK™ Diagnostic Reagents are the primary driver. The others are QDITS™ Analyzers and quantumPACK™ Materials and Equipment.

Who are BioSquare's main competitors?

Emerging players on record are QIAGEN, Hologic, Sekisui Diagnostics and NanoDx. Broad incumbents are BioFire Diagnostics (bioMérieux), Becton Dickinson (BD), Cepheid (Danaher) and Abbott Diagnostics. Direct peers are SD Biosensor and QuidelOrtho.

Does BioSquare have an API?

No public API is recorded for BioSquare.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Korea HeraldHLB Panagene's BioSquare wins FDA nod for rapid strep diagnostic kitBioSquare, a subsidiary of Korea's HLB Panagene, has received FDA registration for its QuantumPACK Easy Strep A rapid diagnostic kit, which detects Group A Streptococcus using fluorescence immunoassay and Quantum Dot technology. The kit is designed for throat swab samples from patients with respiratory infection symptoms and represents the company's second FDA-registered diagnostic product this year following the RSV detection kit in January. HLB Panagene stated it is expanding FDA registrations to establish a foothold in the global in vitro diagnostics market.MedipanaHLB Panagen, targeting the global immunodiagnostics market with the acquisition of 'BioSquare' - Medipana NewsHLB Panajin announced the acquisition of a 90% stake in BioSquare, a precision diagnostic company specializing in quantum dot technology for immunodiagnostics. This transaction expands HLB Panajin's product pipeline by integrating BioSquare's QuantumPACK platform and dedicated analysis equipment into its operations. The move aims to enhance global competitiveness by combining molecular diagnostic expertise with advanced point-of-care testing capabilities.HitnewsHLB파나진, '바이오스퀘어' 인수…"글로벌 면역진단 시장 공략"HLB Panajin announced the acquisition of 90% of BioSquare, a precision diagnostics company utilizing quantum dot technology for disease detection. This move allows HLB Panajin to expand its immunodiagnostic platform and product pipeline by integrating BioSquare's high-sensitivity multiplex detection capabilities. The companies aim to leverage this new technology to enhance their competitiveness in the global diagnostics market.